Hypomethylation-activated cancer-testis gene SPANXC promotes cell metastasis in lung adenocarcinoma

Xuewei Wang1 | Sihan Ju1 | Yao Chen1 | Qufei Qian1 | Caiwang Yan1,2,3 | Shuaizhou Chen1 | Yuting Chang1 | Yide Xu1 | Zijian Ma1,2,3 | Chang Zhang1,2,3 | Na Qin1,2,3 | Yayun Gu1,2,3 | Cheng Wang1,2,3,4 | Erbao Zhang1,2,3 | Zhibin Hu1,2,3

1Department of Epidemiology and Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
2State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China
3Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China
4Department of Bioinformatics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China

Correspondence
Zhibin Hu, Erbao Zhang and Cheng Wang, Department of Epidemiology and Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, No. 818 East Tianyuan Road, Nanjing 211166, China. Emails: zhibin_hu@njmu.edu.cn, erbaozhang@njmu.edu.cn and cheng_wang29@njmu.edu.cn

Funding Information
The Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine); State Key Program of National Natural Science of China, Grant/Award Number: 31530047; National Natural Science Foundation of China, Grant/Award Number: 81702266, 81703295; Top-notch Academic Programs Project of Jiangsu Higher Education Institutions, Grant/Award Number: PPZY2015A067; China Postdoctoral Science Foundation, Grant/Award Number: 2017M610339 and 2018M630584; Jiangsu Planned Projects for Postdoctoral Research Funds, Grant/Award Number: 1701041A; Science Fund for Creative Research Groups of the National Natural Science Foundation of China, Grant/Award Number: 81521004

Abstract
Many studies have shown that there were similarity between tumorigenesis and gametogenesis. Our previous work found that cancer-testis (CT) genes could serve as a novel source of candidate of cancer. Here, by analysing The Cancer Genome Atlas (TCGA) database, we characterized a CT gene, SPANXC, which is expressed only in testis. The SPANXC was reactivated in lung adenocarcinoma (LUAD) tissues. And the expression of SPANXC was associated with prognosis of LUAD. We also found that the activation of SPANXC was due to the promoter hypomethylation of SPANXC. Moreover, SPANXC could modulate cell metastasis both in vitro and in vivo. Mechanistically, we found that SPANXC could bind to ROCK1, a metastasis-related gene, and thus SPANXC may regulate cell metastasis partly through interaction with ROCK1 in LUAD. Together, our results demonstrated that the CT expression pattern of SPANXC served as a crucial role in metastasis of LUAD. And these data further corroborated the resemblance between processes of germ cell development and tumorigenesis, including migration and invasion.

KEYWORDS
cancer-testis, lung adenocarcinoma, metastasis, ROCK1, SPANXC
1  |  INTRODUCTION

Lung cancer is the most common cancer type and the leading cause of cancer death.\(^1\) Lung adenocarcinoma (LUAD) is the most diagnosed histological subtype of non-small-cell lung cancer (NSCLC).\(^2\) Even though rapid development of radiotherapy, chemotherapy and targeted therapy for NSCLC, the overall 5-year survival rate is poor due to limited treatment options, and tumour recurrence and metastasis.\(^3-5\) There is no doubt that the insight of tumorigenesis could provide new and efficacious treatments for NSCLC.

Cancer-testis (CT) genes are a group of genes which show a restrictive expression pattern in testis.\(^6\) Several known cancer-testis antigens have contributed to spermatogenesis and carcinogenesis.\(^6\) CT genes were frequently activated in multiple different tumour types.\(^7\) For example, CT genes MAGE-A3 could serve as an independent prognostic marker for patients of LUAD.\(^8\) Our previous studies systematically defined CT genes in 19 cancer types and investigated their potential role in tumorigenesis.\(^9,10\) We also found that CT long non-coding RNA LIN28B-AS1 could regulate biological function of LUAD cells by direct interaction to IGF2BP1 in LUAD.\(^11\)

SPANXC is a member of the SPANX (sperm protein associated with the nucleus in the X chromosome) gene family.\(^12,13\) SPANX gene family encodes differentially expressed testis-specific proteins. These proteins were activated in prostate, lung and bladder cancers.\(^14\) SPANXC could promote breast cancer cell invasion by interacting with structural proteins lamin A/C.\(^15\) These studies indicated that CT gene SPANXC could exhibit a pivotal role in tumorigenesis. However, the role of SPANXC in LUAD had not yet been established.

Here, we present evidence that the elevated expression of CT gene SPANXC was associated with poor LUAD patient prognosis in TCGA LUAD samples. Further analysis found that promoter hypomethylation could lead to the activation of SPANXC in LUAD samples of TCGA. Moreover, SPANXC could modulate cell metastasis both in vitro and in vivo. Mechanistically, we found that SPANXC could directly interact with ROCK1 in LUAD cells. Together, our study firstly identified that SPANXC is an important CT gene in tumorigenesis of LUAD.

2  |  MATERIALS AND METHODS

2.1  |  The expression of SPANXC in normal tissues and LUAD patients

GTEx databases were used to assess testis-specific expression of SPANXC at transcription level. The expression abundance (FPKM) of genes and transcripts was downloaded from the GTEx project (http://www.gtexportal.org/home/, dbGaP Accession phs000424v6.p1). We obtained the expression of SPANXC in LUAD tissues by analysing RNA sequencing data of LUAD patients from TCGA projects (https://confluence.broadinstitute.org/display/GDAC/Home, 2014-07-13 release). The detailed characteristics of samples from GTEx and TCGA are shown in Table S1. Gene expression of SPANXC is dichotomized into above median and below median expression groups based on median cut-off. Overall survival analysis curves were generated using Kaplan-Meier method with Survival package in R. The survival difference between the dichotomized groups was evaluated using log-rank test. DNA demethylation data of LUAD from TCGA were analysed with the R-package.

2.2  |  RNA extraction, reverse transcription and the quantitative real-time PCR

The total RNA was extracted from tissues or cultured cells with TRIzol reagent (Invitrogen), according to the manufacturer's protocol. One microgram of total RNA was reverse transcribed using PrimeScript RT Reagent Kit with gDNA Eraser (Takara). cDNA was used for subsequent qRT-PCRs (SYBR, TaKaRa) according to the manufacturer’s instructions. Results were normalized to the expression of GAPDH. The rest of primers are listed in Table S2.

2.3  |  Cell culture

Lung adenocarcinoma cell lines A549 and NCI-H1299 were cultured in 1640 medium and DMEM (GIBCO-BRL) supplemented with 10% foetal bovine serum (10% FBS), 100 U/mL penicillin and 100 mg/mL streptomycin in humidified air at 37°C with 5% CO₂.

2.4  |  Transfection of cell lines

The siRNAs and plasmid were transfected into LUAD cells using Lipofectamine2000 (Invitrogen) according to the manufacturer’s instructions. The sequences for siRNAs are listed in Table S1.

2.5  |  Cell proliferation assay

A count of 2000 cells per well was cultured in 96-well plates (Corning Inc), and proliferation was evaluated by CCK8 for every 24 hours. For colony formation assay, a certain number of transfected cells were placed in each well of 6-well plates and maintained in proper media containing 10% FBS for 2 weeks, replacing the medium every 4 days. Colonies were fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich) in PBS for 10 minutes. The colony formation was determined by counting the number of stained colonies. Triplicate wells were measured in each treatment group.

2.6  |  Cell migration and invasion assays

For cell migration and invasion assays, 24-well transwell chambers with 8-μm pore size polycarbonate membrane were used (Corning). Cells were seeded on the top side of the membrane pre-coated with Matrigel (BD) (without matrigel for cell migration assay). Incubation for 24 hours, cells inside the upper chamber were removed with cotton swabs, while cells on the lower membrane surface were fixed and then stained with 0.5% crystal violet solution. Five fields were counted randomly in each well. All assays were performed in triplicate, and the experiment was repeated three times.
2.7 | Co-immunoprecipitation and mass spectrometry (LC-MS/MS) assays

Co-IP experiments were performed using a Pierce™ Classic Magnetic IP/Co-IP Kit (Thermo) according to the manufacturer’s instructions. Briefly, cell pellet was resuspended in Buffer A (10 mmol/L Hepes pH7.5, 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.5 mmol/L DTT and 1 mmol/L PMSF/Cocktail) for 10 minutes on ice, 0.25% NP-40 was added for 5 minutes, and cytosol fraction and nuclear pellets were obtained by centrifugation at 13 000 RPM for 10 minutes. Nuclear pellet was then resuspended in Buffer C (20 mmol/L Hepes pH 7.5, 10% glycerol, 0.42 mol/L KCl, 4 mmol/L MgCl2, 0.2 mmol/L EDTA, 0.5 mmol/L DTT and 1 mmol/L PMSF/cocktail) 20 minutes on ice, and nuclear fraction was obtained after 13 000 RPM 10 minutes centrifugation. Cell fraction was mixed together, and 500 µg of lysate was used for one IP reaction. Antibodies was added, IP was performed on the rotating plate in 4°C for 3 hours, and 20 µL washed Magnetic beads was added and incubated for one hour. Quickly wash four times with Wash buffer (50 mmol/L TrisCl 7.9, 10% glycerol, 100 mmol/L KCl, 0.2 mmol/L EDTA, 5 mmol/L MgCl2, 10 mmol/L β-ME 0.1% NP-40). The expression plasmid of SPANXC was marked by Flag. Antibody for Flag was from Sigma. The elutions of proteins were subjected to mass spectrometric analysis. LC-MS/MS experiments were performed with a LTQ linear ion trap mass spectrometer (Thermo Finnigan) equipped with a microspray source.14

2.8 | In vivo assay

NCI-H1299 cells were stably transfected with overexpression of SPANXC and empty vector and harvested cells and washed with PBS, and resuspended at 2 × 10⁷ cells/mL. Then, the suspended cells were injected into the tail veins of nude mice, which were treated 60 days after injection. The presence of tumour nodules was determined and was counted. Our study was carried out in strict accordance with Guide for Care and Use of Laboratory Animals of the National Institutes of Health. Our project was approved by committee on the ethics of animal experiments of Nanjing Medical University.

2.9 | Statistical analysis

All statistical analyses were performed using SPSS 20.0 software (IBM, SPSS). The significance of differences between groups was estimated by Student’s t test, chi-squared test or Wilcoxon test, as appropriate. Two-sided P-values were calculated, and a probability level of 0.05 was chosen for statistical significance.

3 | RESULTS

3.1 | CT gene SPANXC is activated by promoter hypomethylation and is associated with poor prognosis in LUAD

Firstly, by utilizing transcription data from the GTEx, we found that SPANXC was a typical restricted expression in testis tissues (Figure 1A). Through integrating expression data of LUAD from the TCGA data, we found that SPANXC is frequently activated in LUAD patients (Figure 1B). These results indicated that SPANXC was CT gene and it was activated in LUAD.

Next, we inquired into the association between SPANXC activation and tumorigenesis of LUAD. Further analysis found that patients with higher SPANXC expression had a significantly poorer prognosis than those with lower SPANXC expression (HR = 1.74, P = 0.014, Figure 1C). Based on the methylation data of LUAD from TCGA, intriguingly, we found that the activation of SPANXC was due to the promoter hypomethylation of SPANXC (Figure 1D).

3.2 | CT gene SPANXC regulates LUAD cell metastasis in vitro

To determine the role of SPANXC in tumorigenesis of LUAD, firstly, we determined the SPANXC expression levels in LUAD cell
Then, we performed knockdown of SPANXC via siRNA in A549 cell lines which originally expressed relatively high SPANXC. After transfection with the specific siRNA (Figure 2B), there was no significant difference between treatment group and control group for cell proliferation and colony formation assay in A549 cells (Figure 2C and 2D). However, transwell assays found that knockdown of SPANXC resulted in significantly decreases in migration and invasion in A549 cells (Figure 2E). Conversely, overexpression of SPANXC can significantly promote cell migration and invasion in NCI-H1299 cells (Figure 3A and 3B).

### 3.3 SPANXC promotes cell metastasis in vivo

To further determine whether SPANXC affects cell metastasis in vivo, firstly, NCI-H1299 cells stably transfected with SPANXC expression vector by lentivirus (Figure 3C). We found that lentivirus-mediated stably transfected overexpression of SPANXC could promote cell migration and invasion in NCI-H1299 (Figure 3D). Then, NCI-H1299 cells with overexpression of SPANXC or control vector were injected into the tail veins of nude mice. Metastatic nodules on the surface of the liver were counted after 60 days. The mice injected with overexpression of SPANXC cells succumbed to death more rapidly than the control cells (Figure 4A). And the number of metastatic nodules on the surface of the liver was significantly higher than the control cells (Figure 4B and 4C). Taken together, SPANXC exhibits a pivotal role in cell metastasis of LUAD.

### 3.4 CT gene SPANXC could promote cell metastasis by binding to ROCK1

Our data suggested that SPANXC may play an important role in cell metastasis of LUAD. To explore the mechanism for SPANXC in metastasis of LUAD, we performed co-immunoprecipitation (IP) assays after overexpression of SPANXC, followed by mass spectrometry (MS), to assess the proteins interacting with SPANXC. The results showed that ROCK1 gene was obviously enriched after overexpression of SPANXC than that in control cells (Figure 5A). Then, we further validate the physical interaction between SPANXC and ROCK1 by Co-IP and Western blotting assays (Figure 5B).
Moreover, overexpression of SPANXC could indeed induce ROCK1 protein expression (Figure 5C). And we also found that ROCK1 has significant higher expression in LUAD samples after analysing from TCGA unpaired 488 LUAD tumour and 57 adjacent normal tissues (Figure 5D). ROCK1 has been participated in multiple cellular processes and pathologies, especially in metastasis process of tumorigenesis including LUAD. Our results indicated that SPANXC could promote cell metastasis by binding to ROCK1.

4 | DISCUSSION

The procedure of germ cell formation and tumorigenesis has significant similarities, involving cell immortalization, migration and invasion, induction of meiosis. CT genes have been known as prospective cancer markers and objectives for therapy. The activation of CT gene expression in various types of tumours was observed. Previous study found that the activation frequency of CT gene is much changeful depending on cancer type, the melanomas, the liver and lung cancers could show a high rate of recurrence. More and more studies showed that the activation of CT genes could affect on cells proliferation, apoptosis and metastasis of cancer cells, and also serve as a prognostic indicator. For instance, significantly higher expression of CT gene MAGE-A4 was detected in among squamous cell carcinoma of lung patients displayed obviously poorer survival than those without MAGE-A4 expression.

The SPANX genes could encode differentially testis-specific proteins. SPANXC was a member of SPANX gene family that
was located in Xq27.2.28-30 In our study, we found that SPANXC was a CT gene and was activated in patients of TCGA LUAD. The promoter hypomethylation was an important reason for activation of SPANXC in LUAD. Previous findings also indicated that demethylation is an important mechanism for CT gene reactivation.9,31,32 Then, functional assay in vitro and in vivo confirmed that SPANXC can contribute to the metastasis of LUAD. Mechanistic investigations found that SPANXC could bind to ROCK1 protein. Although it has been proved that SPANXC was a CT gene,29 the molecular mechanism of SPANXC was not clear. We observed that the interaction between SPANXC gene and ROCK1, ROCK1 was an important migration-related gene in tumorigenesis.17 And ROCK1 also participated in epithelial-to-mesenchymal transition (EMT) in tumorigenesis.33,34 Our results provided important evidence that SPANXC could promote the metastasis of LUAD cells, partly through interaction with ROCK1. Therefore, SPANXC may regulate cell metastasis by affecting EMT pathway. Our data further corroborated the resemblance between processes of germ cell development and tumorigenesis, including tumour metastasis.

In summary, CT gene SPANXC could be activated by promoter hypomethylation and indicated poor prognosis in LUAD patients. Moreover, SPANXC could regulate cell metastasis of LUAD both in vitro and in vivo. Our study demonstrated that CT gene SPANXC may be a candidate target for LUAD therapy.

ACKNOWLEDGEMENTS

We thank the TCGA project for use of the data of LUAD samples and the Genotype-Tissue Expression (GTEx) project for use of the expression abundance of multiple normal tissues. This work was supported by the State Key Program of National Natural Science of China (31530047), Science Fund for Creative Research Groups of the National Natural Science Foundation of China (815201004). This work was also supported by National Natural Science Foundation of China (81702266, 81702395), the China Postdoctoral Science Foundation (2017M610339 and 2018M630584), Jiangsu Planned Projects for Postdoctoral Research Funds (1701041A), the Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine), and Top-notch Academic Programs Project of Jiangsu Higher Education Institutions (PPZY2015A067).

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS

ZBH, EBZ and CW involved in conceptualization; WXW, CWY and QFQ involved in methodology; YC, SZC, YTC, SHJ, YDX and YYG performed data curation; WXW, CZ wrote and prepared the original draft; EBZ involved in writing, reviewing and editing; ZBH involved in supervision.

DATA AVAILABILITY

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

ORCID

Erbao Zhang https://orcid.org/0000-0002-5752-7976
Zhibin Hu https://orcid.org/0000-0002-8277-5234

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424
2. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16:e342–e351
3. Borghesi H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
4. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.

5. Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388:1012–1024.

6. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22–32.

7. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:635–625.

8. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11:8055–8062.

9. Wang C, Gu Y, Zhang K, et al. Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. Nat Commun. 2016;7:10499.

10. Qin N, Wang C, Lu Q, et al. Systematic identification of long non-coding RNAs with cancer-testis expression patterns in 14 cancer types. Oncotarget. 2017;8:94769–94779.

11. Wang C, Gu Y, Zhang E, et al. A cancer-testis non-coding RNA LIN28B–AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. Oncogene. 2019;38(10):1611–1624.

12. Salemi M, Calogero AE, Di Benedetto D, et al. Expression of SPANX proteins in human-ejaculated spermatozoa and sperm precursors. Int J Androl. 2004;27:134–139.

13. Salemi M, Calogero AE, Castiglione R, et al. Expression of SpanX proteins in normal testes and in testicular germ cell tumours. International journal of andrology. 2006;29:368–373.

14. Crespi BJ, Summers K. Positive selection in the evolution of cancer. Biol Rev Camb Philos Soc. 2006;81:407–424.

15. Maine EA, Westcott JM, Prechtl AM, Dang TT, Whitehurst AW, Pearson GW. The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion. Oncotarget. 2016;7:14708–14726.

16. Zhang E, He X, Zhang C, et al. A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1. Genome Biol. 2018;19:154.

17. Kamai T, Tsuji T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003;9:2632–2641.

18. Vigil D, Kim TY, Plachko A, et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Can Res. 2012;72:5338–5347.

19. Joshi P, Jeon YJ, Lagana A, et al. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc Natl Acad Sci USA. 2015;112:8650–8655.

20. Kulkarni P, Uversky V. Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers. Int J Mol Sci. 2017;18(4):740.

21. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100:2014–2021.

22. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer immuno. 2004;4:1.

23. Hofmann O, Caballero OL, Stevenson BJ, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA. 2008;105:20422–20427.

24. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res. 1999;5:335–341.

25. D’Arcy P, Maruwege W, Wolahan B, Ma L, Brodin B. Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells. PLoS ONE. 2014;9:e95136.

26. Caballero OL, Cohen T, Gurung S, et al. Effects of CT-Xp gene knock down in melanoma cell lines. Oncotarget. 2013;4:531–541.

27. Shigematsu Y, Hanagiri T, Shiota H, et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer. 2010;68:105–110.

28. Zedman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol. 2003;194:272–288.

29. Kouprina N, Mullokandov M, Rogozin IB, et al. The SPANX gene family of cancer/testis-specific antigens: rapid evolution and amplification in African great apes and hominids. Proc Natl Acad Sci U S A. 2004;101:3077–3082.

30. Westbrook VA, Diekman AB, Naaby-Hansen S, et al. Differential nuclear localization of the cancer/testis-associated protein, SPANX-X/ CTP11, in transfected cells and in 50% of human spermatozoa. Biol Reprod. 2001;64:345–358.

31. Fratta E, Coral S, Covre A, et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Molecular oncology. 2011;5:164–182.

32. Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol. 2014;54:251–272.

33. Bokobza SM, Ye L, Kynaston H, Jiang WG. Growth and differentiation factor 9 (GDF-9) induces epithelial-mesenchymal transition in prostate cancer cells. Mol Cell Biochem. 2011;349:33–40.

34. Li J, Song Y, Wang Y, Luo J, Yu W. MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 2013;380:277–282.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Wang X, Ju S, Chen Y, et al. Hypomethylation-activated cancer-testis gene SPANXC promotes cell metastasis in lung adenocarcinoma. J Cell Mol Med. 2019;23:7261–7267. https://doi.org/10.1111/jcmm.14532